Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LBSR NEWS!
lets work together like a group dont sell at low ..dont you wana make money !!! so hold and sell at high ...let this baby rock!
Yes Yes Yes and Yes :)
yup :) this is time to buy
SHE IS GOING TO ROCK !!!
so its good time to buy ?
there is dtc chill restricting you cant buy or sell stocks
wasup with trading no volume no trade
what are your opinion for next week should we buy share now ? or wait? FB share price will go up or down for next week ...please share your thought
Dead stock
are we getting our money back ??
so now what looks like DOOMS DAY
i did not follow the board for long time can someone explain what happen to this stock
And those that still have some share in this stock what will happen to those shareholders or those shares
Hangover for Big Party Lol i guess great news is coming $$$
Where is everyone ???
whats going on today no volume no trade and stock keep going down is this real deal
News OUT buy at ask and weee we go $$$$
wow -22% down
Any thoughts whats going on with CURX
Whats going ON ???SO SLOW
FEW MIN TO BELL LET TAKE THIS BABY UP UP AND AWAY
OK its falling down
Trade is soo slow cant belive that i can take a tour around the world
$$$NEWS$$$ MILV
CAPE CORAL, Fla. , Nov. 1, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk) announced that it will purchase the exclusive rights to a formula that was developed to restore proper kidney function in people with chronic kidney disease (CKD).
Chronic kidney disease is a growing health problem in the United States . A report by the Centers for Disease Control (CDC) determined that 16.8% of all adults above the age of 20 years have chronic kidney disease. Thus, one in six individuals has kidney disease. By disease stage, the prevalence is as follows: stage 1, 3.1%; stage 2, 4.1%; stage 3, 7.6%; stage 4; and 5, 0.5%. There are over 500,000 persons on dialysis or who have received kidney transplants. The prevalence of chronic kidney disease has increased by 16% from the previous decade. The increasing incidence of diabetes mellitus, hypertension (high blood pressure), obesity, and an aging population have contributed to this increase in kidney disease.
Kidney disease raises the risk of early death, heart attack, stroke, and high blood pressure. CKD causes anemia, bone disease and malnutrition and can lead to kidney failure, which requires ongoing dialysis or a kidney transplant to maintain life. According to the National Institute of Health's U.S. Renal Data System, over 100,000 Americans started dialysis in 2005 while a total of over 485,000 received ongoing dialysis treatment or a kidney transplant, at a cost of $32 billion . The NIH estimates that by 2020 nearly 785,000 people will be receiving treatment for kidney failure, costing an estimated $53.6 billion . The healthcare costs for one person needing dialysis are between $150,000 – $200,000 per year, with annual global dialysis costs exceeding $1 trillion this decade.
Robert deZanger, CEO of Natures Bioceuticals stated "We are confident that this product will make a meaningful contribution to one of the most overlooked diseases known to man. The problem is most people with CKD aren't even aware they have the disease. Studies show that 4 out of 5 people with advanced CKD (i.e. loss of over 50% of kidney function) do not know they have the disease. Unless tested, diagnosed and dialysis or a transplant is available, many of these people only become unwell after severe kidney failure, when death is imminent. People who have taken our formula have shown substantial increases in kidney function in very short time frames. One positive side effect that has been noted is that the product seems to also shrink enlarged prostrate glands. This could be a second market for the product. Obviously, this product should create substantial revenues for the company and we are excited about the possibilities. Capturing just 0.5% of the market could produce revenues in excess of $100,000,000.00 and with the correct marketing program we believe it could be possible to capture a greater percent of the market within the first few years. Upon closing of the purchase we intend to file the patent documents and then immediately proceed with formal clinical trials to document the amazing results obtained to this point."
About Nature's Bioceuticals:
Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.
Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA , or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"
In addition to historical information, this release contains forward-looking statements.
Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC .
Media Contact: Financial Insights Phone Number: 888 656 3509 E-mail: investors@naturesbioceuticals.com www.naturesbioceuticals.com
SOURCE Nature's Bioceuticals
NEWS $$$$$
CAPE CORAL, Fla. , Nov. 1, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk) announced that it will purchase the exclusive rights to a formula that was developed to restore proper kidney function in people with chronic kidney disease (CKD).
Chronic kidney disease is a growing health problem in the United States . A report by the Centers for Disease Control (CDC) determined that 16.8% of all adults above the age of 20 years have chronic kidney disease. Thus, one in six individuals has kidney disease. By disease stage, the prevalence is as follows: stage 1, 3.1%; stage 2, 4.1%; stage 3, 7.6%; stage 4; and 5, 0.5%. There are over 500,000 persons on dialysis or who have received kidney transplants. The prevalence of chronic kidney disease has increased by 16% from the previous decade. The increasing incidence of diabetes mellitus, hypertension (high blood pressure), obesity, and an aging population have contributed to this increase in kidney disease.
Kidney disease raises the risk of early death, heart attack, stroke, and high blood pressure. CKD causes anemia, bone disease and malnutrition and can lead to kidney failure, which requires ongoing dialysis or a kidney transplant to maintain life. According to the National Institute of Health's U.S. Renal Data System, over 100,000 Americans started dialysis in 2005 while a total of over 485,000 received ongoing dialysis treatment or a kidney transplant, at a cost of $32 billion . The NIH estimates that by 2020 nearly 785,000 people will be receiving treatment for kidney failure, costing an estimated $53.6 billion . The healthcare costs for one person needing dialysis are between $150,000 – $200,000 per year, with annual global dialysis costs exceeding $1 trillion this decade.
Robert deZanger, CEO of Natures Bioceuticals stated "We are confident that this product will make a meaningful contribution to one of the most overlooked diseases known to man. The problem is most people with CKD aren't even aware they have the disease. Studies show that 4 out of 5 people with advanced CKD (i.e. loss of over 50% of kidney function) do not know they have the disease. Unless tested, diagnosed and dialysis or a transplant is available, many of these people only become unwell after severe kidney failure, when death is imminent. People who have taken our formula have shown substantial increases in kidney function in very short time frames. One positive side effect that has been noted is that the product seems to also shrink enlarged prostrate glands. This could be a second market for the product. Obviously, this product should create substantial revenues for the company and we are excited about the possibilities. Capturing just 0.5% of the market could produce revenues in excess of $100,000,000.00 and with the correct marketing program we believe it could be possible to capture a greater percent of the market within the first few years. Upon closing of the purchase we intend to file the patent documents and then immediately proceed with formal clinical trials to document the amazing results obtained to this point."
About Nature's Bioceuticals:
Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.
Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA , or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"
In addition to historical information, this release contains forward-looking statements.
Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC .
Media Contact: Financial Insights Phone Number: 888 656 3509 E-mail: investors@naturesbioceuticals.com www.naturesbioceuticals.com
SOURCE Nature's Bioceuticals
O YAA Told you alert in morning see now and thanks me later $$$$$$$$$$$
agreed this is buy time and dont tell me that we did not alert you
BIG DAY IN MORNING HERE COME $$$.10
BUY AT ASK LET TAKE THIS SHIP ALL THE WAY TO SKY TEAM WORK FOR $$$$$$
NEWS LBSR
TIME TO BUY AND THIS ROCK GO $$$$
if you want break the wall bring more volume stock does not go up because everyone on this board already bought there dip and they dont have more money to invest in this stock they all are waiting for huge profit and MM trying keep this down ....this can only be break and we all can get profit if we drag the volume by posting OTOW on all other forms Trust me this will work if you want $$$$...... nothing comes FREE in this work you have to work for your share.
i am really soooooo Disappointed with this Stock so many news’s and this wont move from its place
NEW OUT QSGIQ
PALM BEACH, Fla. , March 24, 2011 /PRNewswire/ -- QSGI, Inc. (Pink Sheets: QSGIQ) announced that on March 21, 2011 its Plan of Reorganization (the "Plan") was confirmed by the U.S. Bankruptcy Court, Southern District of Florida , West Palm Beach . The final order confirming the plan will be recorded as early as today. As part of the Plan, QSGI will merge with KruseCom in a stock-for-stock transaction and is expecting to emerge from bankruptcy in approximately 60 days. Under the plan, stockholders retained their common shares.
According to Marc Sherman who serves as Chairman and CEO of QSGI, Inc. , "The combination of QSGI with its restructured balance sheet and ties to large customers and investment markets and KruseCom with a profitable operation in a corollary business, deep management strength and strong balance sheet will provide a great launching pad to capitalize on the fragmented information technology services market."
About QSGI, Inc. :
QSGI Inc operates as a technology service provider, offering a full suite life-cycle for its corporate and government clients' entire information technology platform. On July 2, 2009 , QSGI, Inc. , along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Florida .
KruseCom, LLC Summary:
Founded in September of 2009, KruseCom offers comprehensive solutions for I.T. Asset Management. KruseCom's specialties include Secure and Certified Onsite Data Erasure, Data Center Maintenance, and End-of-Lifecycle Services for everything in Information Technology.
For further information, please visit: http://www.QSGIInc.com
Forward-Looking Statements:
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as " may," "could," "would," "should," "believes," "expects, " "anticipates," " estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of QSGI to be materially different from historical results or from any results expressed or implied by such forward- looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of mergers, acquisitions, and operations; competition from other technology companies; and the additional risks discussed in filings with the Securities and Exchange Commission . All forward-looking statements are qualified in their entirety by this cautionary statement, and QSGI undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The company names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
SOURCE QSGI, Inc.
/CONTACT: David Meynarez , Chief Financial Officer, QSGI, Inc. , +1-561-629- 5713, ext. 1002, david.meynarez@qsgiinc.com
/Web site: http://www.QSGIInc.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/nae/al?rnd=0XeOnsaXGoWGNpITvxbnpA%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires (212-416-2400)
03-24-11 0730ET
Copyright (c) 2011 Dow Jones & Company, Inc.
NEWS OUT QSGIQ
PALM BEACH, Fla. , March 24, 2011 /PRNewswire/ -- QSGI, Inc. (Pink Sheets: QSGIQ) announced that on March 21, 2011 its Plan of Reorganization (the "Plan") was confirmed by the U.S. Bankruptcy Court, Southern District of Florida , West Palm Beach . The final order confirming the plan will be recorded as early as today. As part of the Plan, QSGI will merge with KruseCom in a stock-for-stock transaction and is expecting to emerge from bankruptcy in approximately 60 days. Under the plan, stockholders retained their common shares.
According to Marc Sherman who serves as Chairman and CEO of QSGI, Inc. , "The combination of QSGI with its restructured balance sheet and ties to large customers and investment markets and KruseCom with a profitable operation in a corollary business, deep management strength and strong balance sheet will provide a great launching pad to capitalize on the fragmented information technology services market."
About QSGI, Inc. :
QSGI Inc operates as a technology service provider, offering a full suite life-cycle for its corporate and government clients' entire information technology platform. On July 2, 2009 , QSGI, Inc. , along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Florida .
KruseCom, LLC Summary:
Founded in September of 2009, KruseCom offers comprehensive solutions for I.T. Asset Management. KruseCom's specialties include Secure and Certified Onsite Data Erasure, Data Center Maintenance, and End-of-Lifecycle Services for everything in Information Technology.
For further information, please visit: http://www.QSGIInc.com
Forward-Looking Statements:
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as " may," "could," "would," "should," "believes," "expects, " "anticipates," " estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of QSGI to be materially different from historical results or from any results expressed or implied by such forward- looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of mergers, acquisitions, and operations; competition from other technology companies; and the additional risks discussed in filings with the Securities and Exchange Commission . All forward-looking statements are qualified in their entirety by this cautionary statement, and QSGI undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The company names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
SOURCE QSGI, Inc.
/CONTACT: David Meynarez , Chief Financial Officer, QSGI, Inc. , +1-561-629- 5713, ext. 1002, david.meynarez@qsgiinc.com
/Web site: http://www.QSGIInc.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/nae/al?rnd=0XeOnsaXGoWGNpITvxbnpA%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires (212-416-2400)
03-24-11 0730ET
Copyright (c) 2011 Dow Jones & Company, Inc.
NEW OUT !!!!
PALM BEACH, Fla. , March 24, 2011 /PRNewswire/ -- QSGI, Inc. (Pink Sheets: QSGIQ) announced that on March 21, 2011 its Plan of Reorganization (the "Plan") was confirmed by the U.S. Bankruptcy Court, Southern District of Florida , West Palm Beach . The final order confirming the plan will be recorded as early as today. As part of the Plan, QSGI will merge with KruseCom in a stock-for-stock transaction and is expecting to emerge from bankruptcy in approximately 60 days. Under the plan, stockholders retained their common shares.
According to Marc Sherman who serves as Chairman and CEO of QSGI, Inc. , "The combination of QSGI with its restructured balance sheet and ties to large customers and investment markets and KruseCom with a profitable operation in a corollary business, deep management strength and strong balance sheet will provide a great launching pad to capitalize on the fragmented information technology services market."
About QSGI, Inc. :
QSGI Inc operates as a technology service provider, offering a full suite life-cycle for its corporate and government clients' entire information technology platform. On July 2, 2009 , QSGI, Inc. , along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Florida .
KruseCom, LLC Summary:
Founded in September of 2009, KruseCom offers comprehensive solutions for I.T. Asset Management. KruseCom's specialties include Secure and Certified Onsite Data Erasure, Data Center Maintenance, and End-of-Lifecycle Services for everything in Information Technology.
For further information, please visit: http://www.QSGIInc.com
Forward-Looking Statements:
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as " may," "could," "would," "should," "believes," "expects, " "anticipates," " estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of QSGI to be materially different from historical results or from any results expressed or implied by such forward- looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of mergers, acquisitions, and operations; competition from other technology companies; and the additional risks discussed in filings with the Securities and Exchange Commission . All forward-looking statements are qualified in their entirety by this cautionary statement, and QSGI undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The company names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
SOURCE QSGI, Inc.
/CONTACT: David Meynarez , Chief Financial Officer, QSGI, Inc. , +1-561-629- 5713, ext. 1002, david.meynarez@qsgiinc.com
/Web site: http://www.QSGIInc.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/nae/al?rnd=0XeOnsaXGoWGNpITvxbnpA%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires (212-416-2400)
03-24-11 0730ET
Copyright (c) 2011 Dow Jones & Company, Inc.
who the Hell dumping share now its buy time and if you want to sell ..then sell at ask
i will say again spread the word in different board and sites more volume can break this down
THIS IS CRAZY I THOUGHT ANY GOOD NEWS TAKE THIS MOTHER TO GREEN BUT NOTHING HAPPEN TO THIS GAINT IT DID NOT EVEN MOVE FROM ITS PLACE WOW
Spread the Word to different boards and sites we need volume